Skip to main content

Table 4 Level of evidence for the 6 drugs with the highest off-label use

From: Off-label use of cancer therapies in women diagnosed with breast cancer in the United States

Drugs Total Total off-label (%) BC specific off-label Level of evidence Primary ICD9 diagnosis code other than BC
Vinorelbine 732 413 (27.0%) 395 Sufficient 147, 184.4, 188, 202.8, 204.1
Carboplatin 444 382 (25.0%) 338 Limited 147, 162, 182, 191, 202.88, 235.7
Bevacizumab 132 199 (13.0%) 222 Limited 162.9, 184.4, 191.92, 202.8
Leuprolide 136 133 (8.7%) 122 Limited 171, 173.3
Liposomal Doxorubicin 104 67 (4.4%) 59 Limited 162.8, 171.9, 202.8
Cisplatin 68 48 (3.1%) 23 Limited 149.8, 150, 151, 162, 170.3, 173.3, 182, 195.0, 201, 202.8, 203,
  1. The total number of off-label encounters and percentage of total encounters is listed for each drug. The level of evidence and recommendation for the off-label use associated to a breast cancer diagnosis were graded as Sufficient, Limited or Inadequate based on the source and strength of the evidence available during the study period. If the off-label encounter was associated to another condition, the ICD-9-CM code was recorded.
  2. 1All bevacizumab encounters before February 22, 2008.
  3. 2Glioblastoma indication approved by FDA (May 05, 2009) after the drug was administered BC = breast cancer.